Re: it still amazes me that
If I understand the Right to try issue, IMGN can sell the drug to those who'd benefit, but I believe they'd need to document actual cost of making it. I believe that's not including developmental costs or the cost of the equipment that's used, essentially it's the costs of the materials used in the process, and the cost of the people and use of the equipment. I could be wrong, but I believe most BP doesn't want to reveal these costs, so they either don't participate in right to try, or they give away the drugs.
I really don't know what IMGN's stance on right to try is, and if they make it available, at what price. I suspect that far more participation in right to try would happen if the FDA established some pricing criteria that made it more desirable to participate. If the cost of the SOC was considered, and the drug makers were allowed to charge some reasonable percentage of the SOC cost, perhaps 50%, it would make participation in the program far more tolerable. If they really wished to push it, they'd dictate that Insurance companies had to pay up to the level of the SOC for experimental treatment.
Gary